欧洲、澳大利亚、英国生殖支原体感染诊疗指南介绍

doi:10.35541/cjd.20190199

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (5): 387-390.doi: 10.35541/cjd.20190199

欧洲、澳大利亚、英国生殖支原体感染诊疗指南介绍

程雨欣李赛苏晓红

中国医学科学院北京协和医学院皮肤病研究所性病科，南京 210042

收稿日期:2019-01-07 修回日期:2019-06-20 发布日期:2020-04-30
通讯作者: 苏晓红 E-mail:suxh@ncstdlc.org
基金资助:
江苏省自然科学基金（BK20170163）

European, Australian and British guidelines for the diagnosis and treatment of Mycoplasma genitalium infections: explanation and comparison

Cheng Yuxin, Li Sai, Su Xiaohong

Department of Sexually Transmitted Disease, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2019-01-07 Revised:2019-06-20 Published:2020-04-30
Contact: Su Xiaohong E-mail:suxh@ncstdlc.org
Supported by:
Natural Science Foundation of Jiangsu Province of China （BK20170163）

摘要/Abstract

摘要： 【摘要】生殖支原体可导致非淋菌性尿道炎、宫颈炎等泌尿生殖道感染甚至附睾炎、盆腔炎、早产等并发症。由于近年来生殖支原体感染率的升高以及多种常用治疗药物耐药的普遍出现，2016年欧洲、2017年澳大利亚性健康联盟、2018年英国性健康与HIV协会分别颁布了生殖支原体感染的诊疗指南，就其感染的临床表现、诊断、患者与性伴的治疗、随访等方面给出了建议，对我国生殖支原体感染的诊治有重要的指导意义。

关键词: 生殖器支原体, 支原体感染, 诊断, 治疗, 指南, 指南解读

Abstract: 【Abstract】 Mycoplasma genitalium can cause non-gonococcal urethritis, cervicitis, and even epididymitis, pelvic inflammatory diseases, preterm birth and other complications. Due to increased prevalence of Mycoplasma genitalium infections and emergence of resistance to a variety of commonly used antibiotics in recent years, European experts, Australian Sexual Health Alliance （ASHA） and British Association for Sexual Health and HIV （BASHH） issued guidelines for the diagnosis and treatment of Mycoplasma genitalium infections in 2016, 2017 and 2018 respectively. These guidelines provide opinions on clinical manifestations and diagnosis of Mycoplasma genitalium infections, treatment and follow-up of patients and partners, which have an important role in guiding the management of Mycoplasma genitalium infections in China.

Key words: Mycoplasma genitalium, Mycoplasma infections, Diagnosis, Treatment, Guidelines, Guideline elaboration

程雨欣李赛苏晓红. 欧洲、澳大利亚、英国生殖支原体感染诊疗指南介绍[J]. 中华皮肤科杂志, 2020,53(5):387-390. doi:10.35541/cjd.20190199

Cheng Yuxin, Li Sai, Su Xiaohong. European, Australian and British guidelines for the diagnosis and treatment of Mycoplasma genitalium infections: explanation and comparison[J]. Chinese Journal of Dermatology, 2020, 53(5): 387-390.doi:10.35541/cjd.20190199

参考文献 18

［1］	Horner PJ, Martin DH. Mycoplasma genitalium infection in Men［J］. J Infect Dis, 2017,216（suppl_2）:S396⁃S405. doi: 10.1093/infdis/jix145.
［2］	Lis R, Rowhani⁃Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta⁃analysis［J］. Clin Infect Dis, 2015,61（3）:418⁃426. doi: 10.1093/cid/civ312.
［3］	苏晓红. 生殖支原体感染诊断和治疗面临的挑战［J］. 中华皮肤科杂志, 2018,51（5）:328⁃331. doi: 10.3760/cma.j.issn.0412⁃4030.2018.05.002.
［4］	Li Y, Su X, Le W, et al. Mycoplasma genitalium in symptomatic male urethritis: macrolide use is associated with increased resistance［J/OL］. Clin Infect Dis, 2019.［2019⁃06⁃18］. https://academic.oup.com/cid/advance⁃article/doi/10.1093/cid/ciz294/5440986. doi: 10.1093/cid/ciz294.
［5］	Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial［J］. Clin Infect Dis, 2013,56（7）:934⁃942. doi: 10.1093/cid/cis1022.
［6］	Sethi S, Zaman K, Jain N. Mycoplasma genitalium infections: current treatment options and resistance issues［J］. Infect Drug Resist, 2017,10:283⁃292. doi: 10.2147/IDR.S105469.
［7］	Murray GL, Bradshaw CS, Bissessor M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium［J］. Emerg Infect Dis, 2017,23（5）:809⁃812. doi: 10.3201/eid2305.161745.
［8］	British Association for Sexual Health and HIV. BASHH launches new NICE accredited guidelines to help prevent Mycoplasma genitalium becoming the next superbug, but funding cuts may hinder implementation［EB/OL］. （2018⁃07⁃13）［2018⁃11⁃20］. https://bashh.org/news/news/bashh⁃launches⁃new⁃nice⁃accredited⁃guidelines⁃to⁃help⁃prevent⁃mycoplasma⁃genitalium⁃becoming⁃the⁃next⁃superbug⁃but⁃funding⁃cuts⁃may⁃hinder⁃implementation/.
［9］	Jensen JS, Cusini M, Gomberg M, et al. 2016 European guideline on Mycoplasma genitalium infections［J］. J Eur Acad Dermatol Venereol, 2016,30（10）:1650⁃1656. doi: 10.1111/jdv.13849.
［10］	ASHA. Australian STI management guidelines for use in primary care［EB/OL］. （2018⁃03）［2018.11.20］. http://www.sti.guidelines.org.au/sexually⁃transmissible⁃infections/mycoplasma⁃genitalium.
［11］	Soni S, Horner P, Rayment M, et al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium （2018）［J］. Int J STD AIDS, 2019,956462419825948. doi: 10.1177/09564624198259 48.
［12］	Golden MR, Workowski KA, Bolan G. Developing a public health response to Mycoplasma genitalium［J］. J Infect Dis, 2017,216（suppl_2）:S420⁃S426. doi: 10.1093/infdis/jix200.
［13］	Bradshaw CS, Jensen JS, Waites KB. New horizons in Mycoplasma genitalium treatment［J］. J Infect Dis, 2017,216（suppl_2）:S412⁃S419. doi: 10.1093/infdis/jix132.
［14］	Couldwell DL, Jalocon D, Power M, et al. Mycoplasma genitalium: high prevalence of resistance to macrolides and frequent anorectal infection in men who have sex with men in western Sydney［J］. Sex Transm Infect, 2018,94（6）:406⁃410. doi: 10.1136/sextrans⁃2017⁃053480.
［15］	The U.S. Food and Drug Administration. FDA permits marketing of first test to aid in the diagnosis of a sexually⁃transmitted infection known as Mycoplasma genitalium ［EB/OL］.（2019⁃01⁃23）［2019⁃06⁃18］. https://www.fda.gov/news⁃events/press⁃announcements/fda⁃permits⁃marketing⁃first⁃test⁃aid⁃diagnosis⁃sexually⁃transmitted⁃infection⁃known⁃mycoplasma.
［16］	TRH R, Fairley CK, Murray GL, et al. Outcomes of resistance⁃guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation［J］. Clin Infect Dis, 2019,68（4）:554⁃560. doi: 10.1093/cid/ciy477.
［17］	Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study［J］. BMJ, 2014,348:g1908. doi: 10.1136/bmj.g1908.
［18］	Falk L, Enger M, Jensen JS. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women［J］. J Antimicrob Chemother, 2015,70（11）:3134⁃3140. doi: 10.1093/jac/dkv246.

[1]	雷杰豪洪为松林福全胡文婷许爱娥. 体外培养节段型白癜风样无色素痣皮损黑素细胞及其临床意义[J]. 中华皮肤科杂志, 2022, 55(9): 798-802.
[2]	樊碧娆陈喜雪王明悦. [开放获取] 米诺环素单药或联合小剂量糖皮质激素治疗红斑型天疱疮15例和疱疹样天疱疮9例疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(8): 676-681.
[3]	曹淼崇杉胡新媛朱学骏王明悦. 副肿瘤性天疱疮患者原发肿瘤切除后皮肤黏膜感染及管理分析[J]. 中华皮肤科杂志, 2022, 55(8): 669-675.
[4]	晋亮刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739.
[5]	徐哲. 对遗传性皮肤病的一些思考[J]. 中华皮肤科杂志, 2022, 55(8): 651-652.
[6]	王媛李志量李锁荆可孙超梁桂熔张寒梅冯素英. 抗p200类天疱疮7例临床及免疫血清学特征分析[J]. 中华皮肤科杂志, 2022, 55(7): 557-561.
[7]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[8]	王玲艳潘靖苗钢常晓丹金秋子郭宁宁张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587.
[9]	吕莎王爽武寒飞张明瑞胡馨李福秋. 孢子丝菌病研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 629-632.
[10]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[11]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[12]	赵柳琦陈妍陈丹阳樊碧娆王瑞尚盼盼陈喜雪朱学骏王明悦. 【开放获取】度普利尤单抗治疗大疱性类天疱疮21例的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(6): 480-485.
[13]	黄馨陈筱昀李亚萍梁兴堃张桂英周英湛意罗帅寒天廖洁月肖嵘龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493.
[14]	温广东冒丹丹张原媛窦沅青赵培吴晨雨张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 55(6): 508-510.
[15]	胡烨蓓宋秀祖. 氨甲环酸治疗黄褐斑的研究进展[J]. 中华皮肤科杂志, 2022, 55(5): 460-462.

欧洲、澳大利亚、英国生殖支原体感染诊疗指南介绍

European, Australian and British guidelines for the diagnosis and treatment of Mycoplasma genitalium infections: explanation and comparison

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 18

相关文章 15

Metrics

本文评价

推荐阅读 10